Cargando…
Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
Autor principal: | Hayanga, J. W. Awori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621176/ https://www.ncbi.nlm.nih.gov/pubmed/37919758 http://dx.doi.org/10.1186/s13054-023-04678-1 |
Ejemplares similares
-
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori, et al.
Publicado: (2023) -
Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry
por: Supady, A., et al.
Publicado: (2023) -
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response
por: Supady, Alexander, et al.
Publicado: (2021) -
Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement
por: Putzu, Alessandro, et al.
Publicado: (2021) -
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement
por: Köhler, Thomas, et al.
Publicado: (2021)